Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer
This trial is active, not recruiting.
|Treatments||hifu (sonablate® 500), brachytherapy|
|Start date||April 2007|
|End date||July 2013|
|Trial size||466 participants|
|Trial identifier||NCT00770822, FSI-002, NCT00485381|
This study will compare high intensity focused ultrasound to standard brachytherapy in the treatment of primary, organ confined prostate cancer.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Birmingham, AL||Brachytherapy Site: Urology Centers of Alabama||no longer recruiting|
|Naples, FL||Brachytherapy Site: Specialists in Urology||no longer recruiting|
|Myrtle Beach, SC||Brachytherapy Site: Grand Strand Urology||no longer recruiting|
|Memphis, TN||HIFU Site: Southeast Urology Network||no longer recruiting|
|Nashville, TN||HIFU Site: Urology Associates||no longer recruiting|
|San Antonio, TX||HIFU Site: Urology of San Antonio||no longer recruiting|
|Endpoint classification||safety/efficacy study|
|Intervention model||parallel assignment|
High Intensity Focused Ultrasound
The primary endpoint will be the absence of biochemical failure, which is defined as a rise of 2.0 ng/mL or more above the PSA nadir and negative biopsy at 24 months.
time frame: 24 Months
Male participants from 40 years up to 75 years old.
Inclusion Criteria: - T1c or T2a carcinoma of the prostate confirmed by biopsy; - life expectancy of 5(five) years or more; - prostate biopsy with 10(ten) or more core biopsies; - Gleason score of 6(six) or less; - serum Prostate Specific Antigen (PSA) of 10(ten)ng/ml or less; - prostate volume of less than 40(Forty)cc; - distance from the Anterior capsule surface to the Posterior capsule surface (AP Diameter) of 40(Forty)cm or less; - informed consent for the treatment study through 24 months post-treatment follow-up Exclusion Criteria: - men who have had previous definitive treatment for prostate cancer; - evidence of metastatic disease and/or a previous positive bone-scan, previous diagnosis or treatment for cancer within the last 5(five) years; - prior hormonal therapy for prostate cancer (including bilateral orchiectomy); - inability to tolerate a transrectal ultrasound; - active urinary tract infection; - functional bladder problems; - prior significant rectal surgery; - intra-prostatic calcifications greater than 1(One)cm in diameter; - interest in future fertility; - prostatic surgery/procedure (except biopsy) within 1(One) year; - large median lobe of the prostate; - use of medications that can affect PSA within 2(Two) months (e.g. finasteride, saw palmetto); - current bladder cancer, urethral stricture, or bladder neck contracture; - urinary tract and/or rectal fistula; - rectal fibrosis/stenosis; - anomaly of the rectal anatomy or mucus membrane; - prostate seroma/abcess; - prostatitis; - compromised renal function or upper urinary tract disease secondary to urinary obstruction; - bleeding disorders/coagulopathy based on measures of PT and PTT; - implant in the prostate or within 1(One)cm of the prostate; - zip code of the primary residence of the subject is greater than 200(Two hundred) miles from the clinical site or transportation that would hinder the completion of the study
|Official title||A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU|
|Principal investigator||Mark Schoenberg, M.D.|
|Description||The proposed study is a prospective, non-randomized concurrently controlled study. The active treatment arm uses the HIFU procedure with the Sonablate device. The control arm uses the brachytherapy procedure. The safety and effectiveness of the Sonablate arm will be compared with the brachytherapy arm. The control arm of the study will be conducted at clinical sites different from the Sonablate arm.|
Call for more information